Article
Immunology
Yu Liu, Minyi Zhang, Meiling Yang, Qing Chen
Summary: The study on adverse events following hepatitis B virus vaccination in Guangdong Province, China from 2005 to 2017 found a low incidence of adverse reactions, with most cases being relatively mild and neurological events being rare.
Article
Biotechnology & Applied Microbiology
Wen Ren, Jing Li, Ruidong Cheng, Zikang Wu, Ying Liu, Yan Qiu, Jun Yao, Jingjing Ren
Summary: The study aimed to evaluate the immunogenicity and persistence of antibodies in adults 8 years after vaccination, finding that isolated anti-HBc-positive subjects could achieve satisfactory long-term immune effects after hepatitis B vaccination, with no significant difference in antibody titers between isolated anti-HBc and control groups after 8 years.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Public, Environmental & Occupational Health
Zhe Dong, Jiang-Rong Li, Zhi-Xian Zhao, Lin Xu, Wen Yu, Wen-Yu Kang, Qiong-Fen Li
Summary: The study investigated the distribution of HBV genotypes and subgenotypes in ethnic minorities in Yunnan province, finding variations in genotype and subgenotype distribution among the 20 ethnic groups, with geographical and ethnic factors influencing genotype distribution.
EPIDEMIOLOGY AND INFECTION
(2021)
Review
Immunology
Rodrigo Velazquez-Moctezuma, Elias H. Augestad, Matteo Castelli, Christina Holmboe Olesen, Nicola Clementi, Massimo Clementi, Nicasio Mancini, Jannick Prentoe
Summary: Hepatitis C virus (HCV) infection causes severe liver-related diseases and leads to a significant number of deaths annually. The lack of an efficient prophylactic vaccine can be attributed to the high genetic variability and escape mutations of the virus, posing challenges to vaccine development efforts.
Article
Biotechnology & Applied Microbiology
Ying Liu, Jingjing Ren, Zikang Wu, Lingzhi Shen, Huan Shan, Xuewei Dai, Jing Li, Yan Qiu, Wen Ren, Jun Yao, Lanjuan Li
Summary: In insular regions of southeast China, the prevalence of hepatitis B can be significantly reduced through large-scale adult HB vaccination. However, there is still a high proportion of susceptible individuals to the HBV virus, so additional measures need to be taken by the government to limit the spread of HBV.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Nicole E. Skinner, Clinton O. Ogega, Nicole Frumento, Kaitlyn E. Clark, Srinivasan Yegnasubramanian, Kornel Schuebel, Jennifer Meyers, Anuj Gupta, Sarah Wheelan, Andrea L. Cox, James E. Crowe Jr, Stuart C. Ray, Justin R. Bailey
Summary: By analyzing the B cell receptors (BCRs) of HCV-infected individuals, researchers identified distinctive BCR features associated with broad neutralization of HCV. These features include long heavy chain complementarity determining region 3 (CDRH3) regions, specific VH gene usage, increased frequencies of somatic hypermutation, and particular VH gene mutations. Further study of these antibodies can inform HCV vaccine development.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Microbiology
Le Chang, Ying Yan, Huimin Ji, Huizhen Sun, Xinyi Jiang, Zhuoqun Lu, Lunan Wang
Summary: This study investigated the prevalence of HDV infection among blood donors in China and found a low seroprevalence rate of HDV infection. The risk of HDV transmission through blood transfusion was also found to be low.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Oncology
Shih-Han Hung, Tzong-Hann Yang, Yen-Fu Cheng, Chin-Shyan Chen, Herng-Ching Lin
Summary: This case-control study investigates the associations between head and neck cancer (HNC), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, and suggests a potential association between HBV and HCV infections and the risk of HNC.
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulze zur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: Bulevirtide treatment reduces HDV RNA and ALT levels in patients with chronic hepatitis D, with a dose-dependent effect.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulzezur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: In this study, it was found that bulevirtide is effective in inhibiting the entry of hepatitis D virus and reducing the progression of liver disease in patients with chronic hepatitis B. The recommended dosage of bulevirtide is 2 mg or 10 mg per day.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Public, Environmental & Occupational Health
Xiaolan Xu, Chensi Wu, Zhuoqi Lou, Chunting Peng, Lushun Jiang, Tianxian Wu, Taiwen Zeng, Yin Dong, Bing Ruan
Summary: The incidence of hepatitis B in rural adults in China is decreasing, but the chronicity rate is relatively high and only one third of individuals develop protective antibodies. Population-based screening and vaccination for susceptible individuals should be emphasized.
Article
Immunology
Anna A. Minta, Maria Wilda T. Silva, Achyut Shrestha, Maricel de Quiroz-Castro, Rania A. Tohme, Mario E. Quimson, Mario Antonio Jiz, Joseph Woodring
Summary: The prevalence of HBsAg among children aged 5-7 in the Philippines has significantly decreased, especially after hepatitis B vaccination. However, timely HepB-BD vaccination still faces challenges and requires strengthened awareness and implementation measures.
Article
Immunology
Yakun Tian, Wei Hua, Yaxin Wu, Tong Zhang, Wen Wang, Hao Wu, Caiping Guo, Xiaojie Huang
Summary: A meta-analysis study found that a double dose and multiple injections of the HBV vaccine were more effective in inducing immune responses in people living with HIV compared to the standard dose. Participants with higher CD4+ T-cell levels showed better vaccine response rates, highlighting the importance of timely HBV vaccination in individuals infected with HIV.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Zhijiang Miao, Zhenrong Xie, Li Ren, Qiuwei Pan
Summary: HDV infection can cause severe hepatitis leading to cirrhosis and hepatocellular carcinoma, requiring advanced scientific knowledge and joint efforts from multi-stakeholders to combat effectively.
CHINESE MEDICAL JOURNAL
(2022)
Article
Cell Biology
Juzeng Zheng, Ziqiang Xia, Yilun Xu, Zhanfan Ou, Xianfan Lin, Sisi Jin, Yang Liu, Jinming Wu
Summary: This study investigated the binding energies and affinities between HBV DNA polymerase epitopes and the HLA-A0201 molecule through molecular docking and experiments. Several epitopes showed low binding energy, while some had high binding affinity. T cells stimulated by specific epitopes were found to induce immune response and suppress HBV, making them promising targets for designing an epitope-based therapeutic vaccine against HBV.